Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 16:12:2079-2085.
doi: 10.2147/OPTH.S184776. eCollection 2018.

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Affiliations

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort

Agustin L Gonzalez. Clin Ophthalmol. .

Abstract

Purpose: The aim of this study was to evaluate the safety and efficacy of lifitegrast 5% ophthalmic solution in improving contact lens discomfort (CLD) in patients wearing a low-modulus, nonionic, monthly replacement silicone hydrogel contact lenses (SHCLs).

Patients and methods: A single center, prospective, open-label study was undertaken on patients wearing monthly replacement, low modulus silicone hydrogel contact lenses. Best-corrected visual acuity (BVA), lissamine staining (LS) and eight item contact lens dry eye questionnaire (CLDEQ-8) scores were assessed at baseline and after 8-week therapy of twice-a-day lifitegrast 5% ophthalmic solution use. Pre- and Posttreatment data were analyzed for statistical significance.

Results: Twenty-one subjects (15 female and six male) with the mean age of 31.7 (±5.29) years completed the study. No reduction or statistically significant change in monocular BVA or LS scores was observed. Data showed a statistically significant (P<0.05) reduction in total CLDEQ-8 score, questions 1A, 1B, 2A and 2B scores and nonstatistically significant reduction in questions 3A, 3B, 4 and 5 scores. Fifteen (n=15, 71.4%) study subjects found the therapy positive for their contact lens wear.

Conclusion: Data suggest the use of topical lifitegrast 5% ophthalmic solution twice a day may be a safe and effective therapeutic intervention for managing patients with CLD in SHCL users; however further research is indicated.

Keywords: contact lens discomfort; contact lens discontinuation; dry eye; lifitegrast.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Agustin L Gonzalez is a consultant and speaker for Shire Ophthalmics and Bausch+Lomb Vision Care. The author reports no other conflict of interest in this work.

Figures

Figure 1
Figure 1
Baseline and final CLDEQ-8 item score. Notes: Comparison of the eight item Contact Lens Dry Eye Questionnaire (CLDEQ-8) Baseline (initial) and final item scores after using lifitegrast 5% ophthalmic solution treatment (data are mean ± SD). A lower score means reduced symptoms. Improvements in items 1a, 1b, 2a, 2b were statistically significant (P<0.05). Abbreviation: CLDEQ-8, eight-item Contact Lens Dry Eye Questionnaire.

References

    1. Nichols JJ, Willcox MD, Bron AJ, et al. The TFOS International Workshop on Contact Lens Discomfort: executive summary. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS7–TFOS13. - PMC - PubMed
    1. Nichols JJ, Jones L, Nelson JD, et al. The TFOS International Workshop on Contact Lens Discomfort: introduction. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS1–TFOS6. - PMC - PubMed
    1. Nichols KK, Redfern RL, Jacob JT, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS14–TFOS19. - PubMed
    1. Craig JP, Willcox MD, Argüeso P, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the contact lens interactions with the tear film subcommittee. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS123–TFOS156. - PubMed
    1. Dumbleton K, Caffery B, Dogru M, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on epidemiology. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS20–TFOS36. - PubMed

LinkOut - more resources